HUTCHMED's Sovleplenib wins FDA orphan drug designation for primary immune thrombocytopenia
HCM•The FDA granted orphan drug designation to HUTCHMED's sovleplenib for primary immune thrombocytopenia, offering seven years of US market exclusivity upon approval and development incentives. Chinese regulators are reviewing applications for the condition and warm antibody autoimmune hemolytic anemia, supported by positive results from the pivotal ESLIM-01 and ESLIM-02 trials.
1. FDA designation
HUTCHMED said the FDA granted orphan drug designation to sovleplenib for primary immune thrombocytopenia, an autoimmune disorder that increases bleeding risk. The designation offers seven years of US market exclusivity upon approval, alongside development incentives.
2. China applications
Chinese regulators are reviewing sovleplenib applications for primary immune thrombocytopenia and warm antibody autoimmune hemolytic anemia. Positive results from China's pivotal ESLIM-01 and ESLIM-02 trials support the respective applications.
